Business
Sera Prognostics Announces Publication Of Data Confirming The Performance Of The IBP4/SHBG Biomarkers In Diverse Non-U.S. Populations
Results confirmed that a U.S. validated proteomics predictor could be applied in low and middle income countries to help address global preterm birth
About this update from Sera Prognostics, Inc.
[{"type":"text","content":"Results confirmed that a U.S. validated proteomics predictor could be applied in low and middle income countries to help address global preterm birth challenges\n\n\nSALT LAKE CITY, Dec. 1, 2021 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced the publication of a study funded by the Bill & Melinda Gates Foundation and in collaboration with AMANHI (Alliance for Maternal and Newborn Health Improvement), a multinational effort to improve health for pregnant and postpartum women and their babies in sub-Saharan Africa and South Asia. The newly published article presents the performance of the IBP4/SHBG biomarker pair in predicting spontaneous preterm birth (sPTB) in low and middle income geographies, with prespecified adjustment for demographic differences between the populations.\n\n \n \n \n \n \n \n\n \n\"Sera is committed to addressing the global challenges of premature births,\" said Gregory C. Critchfield, MD, MS, Chairman and CEO of Sera Prognostics. \"The data published today demonstrate that our biomarkers can be used to predict sPTB in patient populations with baseline demographics and health care access that are distinct from those of U.S. populations in which they were initially validated. We believe that these data warrant careful consideration by all stakeholders who seek to improve maternal and neonatal outcomes and support the further evaluation of these biomarkers in additional populations.\" \nThe PreTRM® test was developed and validated for prediction of spontaneous preterm birth (sPTB) broadly in the U.S. in the Proteomic Assessment of Preterm Risk (PAPR) study. The biomarkers were subsequently shown to be predictive of very early preterm birth of any cause, length of neonatal hospital stay, and neonatal morbidity and mortality in a second large prospective U.S. study, the Multicenter Assessment of a Spontaneous Preterm Birth Risk Predictor (TREETOP) study. Now, analysis of biomarker performance in AMANHI samples, published in the peer-reviewed Journal of Maternal-Fetal & Neonatal Medicine in an article entitled \"Performance of a validated spontaneous preterm delivery predictor in South Asian and sub-Saharan African women: a nested case-co...